CHRS · Company research
Coherus Oncology, Inc. (CHRS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
14records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Eligible shareholders may share proceeds from Coherus' assets tied to similar medicines. The sale process has begun. - Stock Titan | Eligible shareholders may share proceeds from Coherus' assets tied to similar medicines. The sale process has begun. Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Coherus (CHRS) Stock: Slides -0.82%, Support at $1.15 2026-09-17 - VWAP Deviation - https://www.siam.in/ | Coherus (CHRS) Stock: Slides -0.82%, Support at $1.15 2026-09-17 - VWAP Deviation https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Sep 17, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology files $50M at-the-market sales agreement with Leerink Partners - TradingView | Coherus Oncology files $50M at-the-market sales agreement with Leerink Partners TradingView | View source ↗ | TradingView | Aug 28, 2026 | neutral | 0 | 0.6 |
| Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan | Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid Stock Titan | View source ↗ | Stock Titan | Aug 17, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology Announces Special Dividend of Contingent Value Rights Tied to Legacy Biosimilar Asset Sales - Quiver Quantitative | Coherus Oncology Announces Special Dividend of Contingent Value Rights Tied to Legacy Biosimilar Asset Sales Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 17, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance | Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 5, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology Q2 Revenue Rises To $14.3 Million - Quiver Quantitative | Coherus Oncology Q2 Revenue Rises To $14.3 Million Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 5, 2026 | neutral | 0 | 0.6 |
| CHRS Forecast — Price Target — Prediction for 2027 - TradingView | CHRS Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS) - Seeking Alpha | Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS) Seeking Alpha | View source ↗ | Seeking Alpha | May 13, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why – Corrected - Yahoo Finance | Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why – Corrected Yahoo Finance | View source ↗ | Yahoo Finance | Apr 10, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology, Inc. Common Stock (CHRS) Stock Price: Oct 13 Close $1.07 - Gotrade | Coherus Oncology, Inc. Common Stock (CHRS) Stock Price: Oct 13 Close $1.07 Gotrade | View source ↗ | Gotrade | Feb 5, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline? - Simply Wall Street | Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline? Simply Wall Street | View source ↗ | Simply Wall Street | Jan 26, 2026 | neutral | 0 | 0.6 |
| Coherus Oncology Stock Surges Following Analyst Ratings and Clinical Developments - timothysykes.com | Coherus Oncology Stock Surges Following Analyst Ratings and Clinical Developments timothysykes.com | View source ↗ | timothysykes.com | Jan 24, 2026 | neutral | 0 | 0.6 |
| There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise - Simply Wall Street | There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise Simply Wall Street | View source ↗ | Simply Wall Street | Jan 10, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.